Lung cancer is the leading cause of cancer-related mortality not only in the United States but also around the world (Humam Kadara,Mohamed Kabbout,&Ignacio Wistuba ,2011). Lung adenocarcinomas are a major subtype of non-small-cell lung cancers, are increasing in incidence globally in both males and females and in smokers and non-smokers, and are the cause for almost 50% of deaths attributable to lung cancer and the high mortality of this disease is in part due to the late diagnosis of the majority of lung cancers after regional or distant spread of the malignancy (Humam Kadara,Mohamed Kabbout,&Ignacio Wistuba 2011). Joseph E.Tota (2013) stated that by far, the most important risk factor for lung cancer is smoking data from screening trials have shown that the risk of death from lung cancer can be reduced by approximately 20% when CT screening is applied to higher-risk patients (J.G. Ravenel, Ed, 2013).
Yorder & Linda H, (2006) described one of the classification of Non small cell cancer lung cancer is Adenocarcinoma tumors which are peripheral in origin, arising from the alveolar surface epithelium or bronchial mucosal glands. Treatment is based on staging and cell type; both anatomic and physiologic For staging purposes for NSCLC the American College of Radiology recommends the following imaging CT chest scan with contrast, if there are no strong contraindications, and a FDG-PET from skull base to midthigh. (Usatine R.P., Smith M.A., Chumley H.S. & Mayeaux E.J., Jr., 2013). Lung cancer remains a major public health problem as the number one cancer killer in both men and women. Primary prevention achieved by smoking ending and smoking prevention is the only well-established mechanism of reducing the number of people affected by lung cancer. The goal of lung cancer screening is to detect the disease at an early stage, when cure is possible, so as to reduce deaths due to lung cancer.
Clin, B., Morlais, F., & Guittet, L.